-
Hypoxia and Immunometabolism in Tumors
2026-08-17
This 2025 Cancer Letters review explains how oxygen limitation and nutrient competition jointly reprogram tumor and immune-cell metabolism in the tumor microenvironment. Its main practical contribution is a systems-level framework connecting HIF signaling, glucose use, immune dysfunction, and therapeutic resistance, while highlighting experimental variables that should be controlled in translational models.
-
Deferasirox: Oral Iron Chelator Mechanisms
2026-08-16
Deferasirox is an oral iron chelator that binds trivalent iron and supports research on iron overload, lysosomal iron handling, and cancer biology. The TCF25 study provides a mechanistic framework for glucose-starvation-induced ferritinophagy and lysosomal cell death, but it did not directly test deferasirox.
-
Olfr110 Structures Reveal Fatty Acid Odor Sensing
2026-08-15
Han et al. use cryo-electron microscopy to define how the class II olfactory receptor Olfr110 recognizes hydrophobic unsaturated fatty acid metabolites and couples ligand binding to G-protein activation. The study identifies a large, chemically heterogeneous binding pocket, conserved recognition motifs, and an activation pathway that differs from canonical class A GPCRs, providing a structural framework for interpreting fatty acid odor detection.
-
2'3'-cGAMP for STING Assay Design
2026-08-14
Use 2'3'-cGAMP (sodium salt) as a direct, high-affinity STING stimulus to separate cGAS, STING, TBK1, and IRF3 effects in innate immune assays. This workflow combines pathway benchmarking with a practical strategy for investigating REC8-dependent antiviral signaling and translational immunotherapy research.
-
O-GlcNAcylation Rewires Wnt-Driven Bone Formation
2026-08-14
The reference study identifies O-GlcNAcylation as a metabolic effector of Wnt-stimulated osteogenesis, linking Wnt signaling to aerobic glycolysis through stabilization of PDK1 at Ser174. Its combination of temporal signaling analysis, lineage-specific genetics, metabolic measurements, and bone-healing models provides a mechanistic framework for studying glucose metabolism in bone formation.
-
RRP Restores Lipid Metabolism in HIRI
2026-08-13
A Journal of Ethnopharmacology study shows that Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury by coordinating AMPK activation, suppression of SCAP-SREBP2 cholesterol synthesis, and LXRα-dependent cholesterol efflux. Its oleic acid–palmitic acid hepatocyte model provides a useful framework for studying lipotoxicity, while the mouse data connect lipid remodeling with tissue protection.
-
Resibufogenin Blocks NLRP3 in Atherosclerosis
2026-08-13
The reference study identifies resibufogenin as a potential anti-atherosclerotic agent that acts by interfering with NLRP3 inflammasome assembly rather than solely modifying lipid metabolism. Using ApoE-/- mice, macrophage-based cellular models, molecular docking, and surface plasmon resonance, the authors connect RBG binding at NLRP3 CYS-279 with reduced inflammation, foam-cell formation, and plaque pathology.
-
T. pallidum, Mitochondrial ROS, and Hepatocyte Apoptosis
2026-08-12
This study identifies mitochondrial reactive oxygen species accumulation and cardiolipin peroxidation as central features of Treponema pallidum-induced intrinsic apoptosis in hepatocytes. Its combination of apoptosis, mitochondrial function, ATP, ROS, and cardiolipin readouts provides a useful framework for dissecting infection-associated liver injury while highlighting the need for validation beyond an immortalized cell model.
-
Alternariol and Hepatic Stellate Cell Fibrosis
2026-08-12
The reference study links Alternariol (AOH) and alternariol monomethyl ether to hepatic stellate cell activation, myofibroblast-like transdifferentiation, and fibrotic signaling, while tenuazonic acid showed no significant effect in the same model. Its lncRNA–mRNA omics framework and CotA laccase detoxification concept extend Alternaria toxin research from general cytotoxicity toward mechanisms of liver fibrosis and mitigation.
-
Palonosetron hydrochloride: 5-HT3 Assay Workflows
2026-08-11
Palonosetron hydrochloride combines subnanomolar 5-HT3 receptor activity with a long-acting pharmacological profile, making it useful for receptor, antiemetic, and transporter studies. This practical guide translates those properties into assay setup, translational workflows, and troubleshooting strategies for cancer research.
-
REV1–DHX36 Coordination of G-Quadruplex Tolerance
2026-08-11
A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. The findings establish a two-tier model for G4 tolerance and clarify how REV1 deficiency amplifies replication stress, ATM/ATR signaling, and sensitivity to G4-stabilizing agents.
-
Thiamet G Workflows for O-GlcNAc Research
2026-08-10
Thiamet G enables controlled O-GlcNAcase inhibition across cell, disease, and animal workflows, from tauopathy assays to leukemia drug-sensitization studies. This guide translates a new ferroptosis and trophoblast study into practical assay design, dose-finding, controls, and troubleshooting strategies.
-
CLCC1 and Herpesvirus Nuclear Egress Fusion
2026-08-09
The reference preprint identifies the host protein CLCC1 as an essential factor for the membrane-fusion step of herpesvirus nuclear egress, addressing a major gap left by the established model of viral nuclear budding. Genetic screening and cellular phenotyping connect CLCC1 loss to perinuclear capsid accumulation, reduced viral production, and impaired nuclear pore complex insertion, while also suggesting an evolutionarily conserved role in nuclear-envelope morphogenesis.
-
Acetylcysteine for Reliable Cell Assays
2026-08-08
Learn how Acetylcysteine (NAC; SKU A8356) can improve the interpretation of cell viability, proliferation, and oxidative-stress experiments through controlled dosing, appropriate assay controls, and evidence-based workflow design. The article uses a 2024 HEI-OC1 senescence study to connect ROS modulation with practical laboratory decisions.
-
Vemurafenib (PLX4032) in Melanoma Research
2026-08-07
Vemurafenib (PLX4032) enables controlled BRAF V600-mutant signaling perturbation for melanoma cell proliferation inhibition, resistance profiling, and translational xenograft studies. This workflow connects dose-response assays with early phospho-signaling and multi-omics readouts to distinguish target engagement from adaptive resistance.